Featured Research

from universities, journals, and other organizations

Stem Cells Correct Defect In Child’s Fatal Skin Disease

Date:
June 23, 2008
Source:
Columbia University Medical Center
Summary:
Researchers and clinicians have paved the way toward a cure for a young boy's genetic and fatal skin disease, recessive dystrophic epidermolysis bullosa (RDEB), by using a cord blood and bone marrow transplant.

Researchers and clinicians have paved the way toward a cure for a young boy’s genetic and fatal skin disease, recessive dystrophic epidermolysis bullosa (RDEB), by using a cord blood and bone marrow transplant. Nate Liao, 25 months old from Clarksburg, N.J., underwent the experimental therapy in October 2007, as the result of a research and clinical collaboration between researchers at Columbia University Medical Center in New York and Thomas Jefferson University in Philadelphia and physicians at the University of Minnesota and University of Minnesota Children’s Hospital, Fairview.

Children with RDEB have skin that is exquisitely delicate because of a genetic defect that results in the absence of a critical protein called collagen type VII, which anchors the skin and lining of the gastrointestinal (GI) system to the body. Without collagen type VII, the skin of people with RDEB is extraordinarily fragile; tearing and blistering occur with minimal friction.

RDEB is associated with painful wounds, mutilating scaring, malnutrition due to the erosion of the esophagus, and frequent infections, so to minimize the risk of tears and blistering those affected must have their entire body continuously wrapped in bandages. Up until now, there have been no successful treatments for children with RDEB and it is always fatal due to malnutrition, infection or eventually an aggressive skin cancer.

In this trial, through the infusion of marrow stem cells obtained from a healthy donor, transplanted stem cells produce collagen type VII and correct the underlying genetic defect.

“We have established a new standard of care for these EB patients, beginning with Nate,” said John Wagner, M.D., the lead University of Minnesota Medical School physician who developed the clinical trial. “Nate’s quality of life is forever changed.”

The concept of using circulating stem cells to treat a skin disease like RDEB was introduced by Angela M. Christiano, Ph.D., professor of dermatology and genetics and development at Columbia University Medical Center, who has been involved in the study of the genetics of RDEB for more than 15 years. Her laboratory performed the first genetic studies on the Liao family and determined the exact molecular basis for their individual case of RDEB. She has studied several gene therapy approaches for RDEB in the past before turning her attention to circulating stem cells.

“This is the first time physicians have approached the treatment of RDEB or any similar skin disease, from a systemic perspective, using marrow-derived stem cells as a means to replace the missing protein, collagen type VII, throughout the body,” said Dr. Christiano.

The groundbreaking research leading up to the clinical trial required that the investigators first showed evidence of a benefit of stem cell therapy in a mouse model of RDEB. Collaborating with Christiano, University of Minnesota researchers Jakub Tolar, M.D., Ph.D., and Bruce Blazar, M.D., discovered that certain stem cells found in bone marrow could correct the biochemical defect in RDEB. The mouse model of RDEB was generated specifically for the purpose of testing novel RDEB therapies, by the laboratory of Jouni Uitto, M.D., Ph.D., professor and chair, Department of Dermatology and Cutaneous Biology, at Thomas Jefferson University in Philadelphia. Analysis also was performed at Asahikawa Medical College in Asahikawa, Japan.

Using the RDEB mouse, Drs. Tolar and Blazar showed that delivering marrow-derived stem cells in the bloodstream greatly lengthened the life expectancy of the mice, and also healed existing blisters. Using the positive results from the RDEB animal model, Dr. Wagner’s team at UMN then designed a clinical trial to test stem cell therapy for RDEB for the first time in patients suffering from the disease; Nate being the first in the trial.

Drs. Christiano and Uitto are experts in the genetic basis of different forms of EB, and their work together has included identification of the human and mouse type VII collagen genes, establishing type VII collagen gene mutations as the molecular basis for dystrophic forms of EB, leading to the development of DNA-based diagnostic tests for EB and eventually to pre-clinical animal models, through research supported from Dystrophic Epidermolysis Bullosa Research Association of America (DebRA of America) and the National Institutes of Health. Dr. Christiano’s ongoing work on stem cell therapy for RDEB and other disorders is supported by the New York State Foundation for Science, Technology and Innovation (NYSTAR).

“The work announced today is the culmination of several years of preclinical work supported in part by the DebRA of America, specifically, the development of a mouse model that recapitulates the features of RDEB, including severe skin blistering at birth,” said Mary Sprague, executive director of DebRA. “DebRA of America is pleased that its support to fundamental basic research in EB has facilitated this major achievement towards treatment, and eventually a cure, for RDEB.”


Story Source:

The above story is based on materials provided by Columbia University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Columbia University Medical Center. "Stem Cells Correct Defect In Child’s Fatal Skin Disease." ScienceDaily. ScienceDaily, 23 June 2008. <www.sciencedaily.com/releases/2008/06/080620213845.htm>.
Columbia University Medical Center. (2008, June 23). Stem Cells Correct Defect In Child’s Fatal Skin Disease. ScienceDaily. Retrieved April 19, 2014 from www.sciencedaily.com/releases/2008/06/080620213845.htm
Columbia University Medical Center. "Stem Cells Correct Defect In Child’s Fatal Skin Disease." ScienceDaily. www.sciencedaily.com/releases/2008/06/080620213845.htm (accessed April 19, 2014).

Share This



More Health & Medicine News

Saturday, April 19, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

'Holy Grail' Of Weight Loss? New Find Could Be It

'Holy Grail' Of Weight Loss? New Find Could Be It

Newsy (Apr. 18, 2014) In a potential breakthrough for future obesity treatments, scientists have used MRI scans to pinpoint brown fat in a living adult for the first time. Video provided by Newsy
Powered by NewsLook.com
Little Progress Made In Fighting Food Poisoning, CDC Says

Little Progress Made In Fighting Food Poisoning, CDC Says

Newsy (Apr. 18, 2014) A new report shows rates of two foodborne infections increased in the U.S. in recent years, while salmonella actually dropped 9 percent. Video provided by Newsy
Powered by NewsLook.com
Scientists Create Stem Cells From Adult Skin Cells

Scientists Create Stem Cells From Adult Skin Cells

Newsy (Apr. 17, 2014) The breakthrough could mean a cure for some serious diseases and even the possibility of human cloning, but it's all still a way off. Video provided by Newsy
Powered by NewsLook.com
Obama: 8 Million Healthcare Signups

Obama: 8 Million Healthcare Signups

AP (Apr. 17, 2014) President Barack Obama gave a briefing Thursday announcing 8 million people have signed up under the Affordable Care Act. He blasted continued Republican efforts to repeal the law. (April 17) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins